check_circleStudy Completed

Non Hodgkin Lymphoma

Bayer Identifier:

16790

ClinicalTrials.gov Identifier:

NCT02155582

EudraCT Number:

2013-004746-42

EU CT Number:

Not Available
Copanlisib pharmacodynamic study

Trial purpose

This study aims to analyze what the study drug does to the body and its relationship to drug levels and safety after patients with advanced cancer have been treated with copanlisib in different dose groups.

Key Participants Requirements

Sex

Both

Age

18 - 100 Years
  • - Histologically confirmed diagnosis of the following NHL: follicular lymphoma all grades, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, transformed indolent lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, mantle cell lymphoma, or peripheral T-cell lymphoma, relapsed or refractory, with 1 or more prior chemo-immunotherapy- or immunotherapy-based regimen(s)
    OR
    - Advanced and / or refractory solid tumors with high prevalence (≥30%) of PIK3CA or PTEN alteration: Breast and uterine cancers (endometrium cancers but also non-endometrial uterine cancers), lung (squamous cell only), cervical, head and neck, prostate, and ovarian cancers
    - Biopsy-accessible tumor
    - Male or female patients equal 18 or more years of age
    - NHL patients must have at least 1 bi-dimensionally measurable lesion according to the modified Cheson criteria. Patients with solid tumors must have at least 1 solid tumor lesion measurable by computed tomography or magnetic resonance imaging according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria
    - Eastern Cooperative Oncology Group performance status 2 or <
    - Life expectancy of at least 3 months
    - Adequate bone marrow, liver, and renal functions as assessed by laboratory requirements conducted within 7 days before the first dose of study drug
    - Left ventricular ejection fraction > or equal the lower limit of normal for the institution

  • - Previous or concurrent cancer that is distinct in primary site or histology from NHL or the solid tumor, for which the patient is enrolled into this study, within 5 years before treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, in situ breast cancer, in situ prostate carcinoma if Gleason score < or equal to 6 and prostate-specific antigen <10 ng/mL, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)]
    - Known lymphomatous involvement of the brain or leptomeningeal involvement; solid tumor patients with central nervous system (CNS) metastases if treatment completed <3 months before enrollment or lesions unstable or progressing on magnetic resonance imaging scans performed within 1 month of enrollment or unstable symptoms of the CNS metastases
    - Any illness or medical condition that is unstable or could jeopardize the safety of the patient or his / her compliance in the study
    - Current diagnosis of type 1 or type 2 diabetes mellitus with HbA1c < or equal to 8.5% or fasting blood glucose < or equal to 160 mg/dL

Trial summary

Enrollment Goal
63
Trial Dates
August 2014 - March 2017
Phase
Phase 1
Could I Receive a placebo
No
Products
Aliqopa (Copanlisib, BAY80-6946)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
LILLE, 59037, France
Completed
BRUXELLES - BRUSSEL, 1000, Belgium
Completed
BRUXELLES - BRUSSEL, 1200, Belgium
Completed
GENT, 9000, Belgium
Completed
CAEN CEDEX 5, 14076, France
Completed
PIERRE BENITE, 69495, France
Completed
Sutton, SM2 5PT, United Kingdom
Completed
London, W1G 6AD, United Kingdom
Completed
NICE CEDEX 2, 06102, France

Primary Outcome

  • Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy
    date_rangeTime Frame:
    Baseline and approximately 2 years
    enhanced_encryption
    Safety Issue:
    No
  • Maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy
    date_rangeTime Frame:
    Baseline and after day 22
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • AUC(0-168) of copanlisib after each copanlisib IV infusion during 2 cycles of copanlisib monotherapy
    date_rangeTime Frame:
    After day 22
    enhanced_encryption
    Safety Issue:
    No
  • AEs as characterized by type, frequency, severity (as graded by CTCAE) and relationship to study drug
    date_rangeTime Frame:
    Approximately 2 years
    enhanced_encryption
    Safety Issue:
    No
  • Maximum change from baseline in insulin during 2 cycles of copanlisib
    date_rangeTime Frame:
    After day 22
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum change from baseline in C-peptide during 2 cycles of copanlisib
    date_rangeTime Frame:
    After day 22
    enhanced_encryption
    Safety Issue:
    Yes
  • FDG PET early response (decreased SUVmax compared to baseline) after dosing with copanlisib for non-diabetic patients with detectable FDG tumor uptake at baseline
    date_rangeTime Frame:
    After day 22
    enhanced_encryption
    Safety Issue:
    No
  • Change from baseline in expression and / or phosphorylation of PI3K pathway proteins in paired tumor biopsies
    date_rangeTime Frame:
    Baseline and after day 22
    enhanced_encryption
    Safety Issue:
    No

Trial design

A Phase I pharmacodynamic study of copanlisib (BAY 80-6946) as monotherapy in patients with non-Hodgkin’s lymphoma and solid tumors
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Other
Allocation
Randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
2

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.